CytomX Therapeutics, Inc. (CTMX): Price and Financial Metrics

CytomX Therapeutics, Inc. (CTMX): $1.37

0.01 (-0.72%)

POWR Rating

Component Grades








Add CTMX to Watchlist
Sign Up

CTMX Price/Volume Stats

Current price $1.37 52-week high $5.85
Prev. close $1.38 52-week low $1.04
Day low $1.33 Volume 1,671,300
Day high $1.40 Avg. volume 4,036,305
50-day MA $2.10 Dividend yield N/A
200-day MA $1.70 Market Cap 106.75M

CTMX Stock Price Chart Interactive Chart >

CytomX Therapeutics, Inc. (CTMX) Company Bio

CytomX Therapeutics develops a novel class of antibody therapeutics based on its Probody technology platform that address clinically-validated cancer targets in immuno-oncology. The company was founded in 2008 and is based in San Francisco, California.

CTMX Latest News Stream

Event/Time News Detail
Loading, please wait...

CTMX Latest Social Stream

Loading social stream, please wait...

View Full CTMX Social Stream

Latest CTMX News From Around the Web

Below are the latest news stories about CYTOMX THERAPEUTICS INC that investors may wish to consider to help them evaluate CTMX as an investment opportunity.

CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 5:15 p.m. PT. A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at ww

Yahoo | December 21, 2023

Investors in CytomX Therapeutics (NASDAQ:CTMX) have unfortunately lost 90% over the last five years

CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shareholders should be happy to see the share price up 26% in the last month...

Yahoo | December 11, 2023

Pfizer (PFE), Arvinas Post Upbeat Data From Breast Cancer Study

Interim data from an early-stage study shows that treatment with Pfizer (PFE)/Arvinas' (ARVN) breast cancer combination therapy demonstrates encouraging clinical activity in heavily pre-treated patients.

Yahoo | December 6, 2023

Alterity (ATHE) Up on Preclinical Parkinson's Treatment Data

Data from a preclinical study shows that treatment with Alterity's (ATHE) lead candidate improved motor performance and general function in monkeys with experimentally-induced Parkinson's disease.

Yahoo | December 5, 2023

CRISPR (CRSP) to Focus on Next-Generation CAR T Pipeline

Based on early data from ongoing clinical studies, CRISPR (CRSP) has decided to focus on the development of its next-generation CAR T pipeline and discontinue its first-generation CAR T candidates.

Yahoo | December 5, 2023

Read More 'CTMX' Stories Here

CTMX Price Returns

1-mo -27.51%
3-mo -39.65%
6-mo -2.84%
1-year N/A
3-year -80.92%
5-year -87.34%
YTD -11.61%
2023 -3.13%
2022 -63.05%
2021 -33.89%
2020 -21.18%
2019 -44.97%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!